cyrilzakka/clinical-trials huggingface dataset:
Learning Through Gamification in Higher Education

"Health care legislation, management and administration" is a basic subject offered in the physical therapy university degree. The juridical features of this subject usually provokes a lack of motivation between students. Although not commonly used in university teaching, gamification could provide further affordances for improving students' engagement which provokes better assistance and learning outcomes.

* 51 students of "Health legislation, management and administration" subject of the Physical Therapy University Degree of the Catholic University of Murcia will be recruited.
* Participants will be randomly assigned into two groups: control group (traditional teaching methods) and intervention group (gamification).
* Class attendance and academic results will be register for future analysis.

Eligibility Criteria:
Inclusion Criteria:

* Students enrolled in the subject during academic year 19-20.
* Students included must not have taken the subject before.
* Students must be able to understand and speak the Spanish language.

Exclusion Criteria:

-
Fit for Everyday Life - Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer

The aim of the study is to increase the physical activity and exercise of those recovering from cancer (after treatments) and to promote a functional return to everyday life and coping in everyday life. The aim of the study is to evaluate the effects of a exercise intervention on the quality of life, functional fitness (functional muscle strength and endurance tests) and the amount of physical activity of the participants in the study.

Design: This is a quantitative study, whose data includes structured surveys (questionnaires) and measurements. Data are collected before and after the group exercise intervention. This 8 week tailored, progressive program will consist muscle strength training, endurance training, flexibility training, relaxation and home-exercises.

Eligibility Criteria:
Inclusion Criteria:

* Active cancer treatments have ended under 12 months
* Age 18-70 years
* Finnish speaking
* moving without aids
* z=1-0
* able to come Meri-Karina
* normal or low physical activity
* able to use digital equipments to participate remote exercise sessions

Exclusion Criteria:

* Exercise contraindications
* Memory and mental health problems
* Exercise every day over two hours
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis


Eligibility Criteria:
Inclusion Criteria:

* Men and Women of nonchildbearing potential 18 years or older.
* Physician Area and Severity Index (PASI) greater than 11.
* Physician Global Assessment (PGA) greater than 3.

Exclusion Criteria:

* Use of any investigational small -molecule drug within 30 days before the first dose of test article administration, and use of any investigational biologic agents within 5 half lives before study day 1, or 90 days for investigational biologics that may have a long clinical duration of effect.
* Live vaccines within 3 months before test article administration or during the study.
* Use of any biologic therapy within approximately 5 half-lives before test article administration. Approximate half-lives of biologic therapies approved for psoriasis are as follows: Enbrel, 5 days; Humira, 14 days; Remicade, 9 days; Amevive, 12 days; Raptiva, 6 days. It is recommended that Amevive be discontinued for at least 90 days because of its long clinical duration of action.
* Psoralen plus ultraviolet A radiation (PUVA) therapy within 4 weeks before study day 1.
* Ultraviolet B (UVB) therapy within 2 weeks before study day 1.
* Receipt of systemic psoriasis therapy (eg, oral retinoids, methotrexate, hydroxyurea, cyclosporine, or azathioprine) or systemic corticosteroids within 4 weeks before study day 1.
* Topical steroids, topical vitamin A or D analog preparations, or anthralin within 2 weeks before study day 1. (Exception: topical therapies, including steroids at no higher than mild strength \[class 6 or 7 topical corticosteroids\], are permitted on the scalp, axillae, face, and groin, but the dose of the medication must be kept stable throughout the trial.)
Intracavitary Fluid and Position of C-section-scar

Does the presence of intracavitary fluid during hormonal stimulation for IVF depends on the position of C-section-scar ?

To evaluate the correlation between the presence of intracavitary fluid and the position of the C-section-scar in relation to the uterine fundus and the inner cervical os.

To this end, we will compare measured variables, in patients with intracavitary fluid and without intracavitary fluid.

Eligibility Criteria:
Inclusion Criteria:

* Patients above an age of 18 years.
* Patients performing IVF treatment.
* One or multiple C-sections.
* C-scar region visible during trans-vaginal scan.

Exclusion Criteria:

* Patients who were IUD carriers in the last 3 months.
Evaluation of the Effect of Conversational Hypnosis When Changing Tracheal Cannula in Adult Patients

Tracheotomy is requested when upper aero-digestive tracts are obstructed. This obstruction can have a tumour, infectious, inflammatory, traumatic or nervous origin. Most tracheotomy surgeries are performed for tumour-induced obstruction. Tracheotomy allows the setting of a respiratory flux thanks to a cannula and excludes the upper airways. The cannula is washed every day from once to several times depending on the patient's secretions production and it is usually replaced every week. The second replacement takes place about 10 days after surgery. Patient education takes place at every replacement in order to empower him/her and in consequence to increase living comfort. This empowerment is achieved at the 4th or 5th replacement, at best. Because of the risks and complications related to tracheotomy and because of the concerned vital function, the cannula replacement leads to anxiety especially during the first replacements. Usual patient's anxiety management consists in reassuring the patient during the replacement. In other situations, patients' anxiety management would be drugs, however due to sedative and anxiolytic drugs' adverse events and to the need to maintain optimal breathing, they are not used in first intention. Our choice is to use conversational hypnosis during cannula replacement as it has already demonstrated interesting effects in pain and anxiety. Conversational hypnosis does not present an induction phase like in so-called hypnosis, it aims at leading the patient to perceive his/her world differently with only a slight consciousness alteration.

Once the informed consent form is signed and when the cannula replacement has to be performed, conversational hypnosis session will start right from the patient's room entrance and end when the nurse will come out. The care will consist in aspiration, cleaning and finally replacement of the cannula. Adverse events are expected to be related to the cannula replacement itself: patients will be followed-up during a maximum of 7 days with one follow-up visit which will take place 2 hours after cannula replacement and a second one which can take place from the day after the replacement up to just before the following replacement.

Eligibility Criteria:
Inclusion Criteria:

* patients hospitalised in the Ear, Nose, Throat - specialties surgery department
* aged of 18 years old and more
* having a tracheotomy following an upper aero-digestive tracts obstruction
* presenting a tracheal cannula which can be replaced by paramedical staff
* able to communicate to give their consent
* member or beneficiary of a social security assurance
* having given a signed informed consent form

Exclusion Criteria:

* patients presenting a hearing loss (preventing from hearing properly the words pronounced during conversational hypnosis)
* who do not understand French
* who are under curators/guardianship
* presenting dementia
* autonomous in their cannula replacement
* having already participated in the study
A Study of MK0359 in Patients With Chronic Asthma (0359-013)

A study to test the effect of MK0359 in lessening the symptoms of asthma as compared to placebo.


Eligibility Criteria:
Inclusion Criteria:

* You are between the ages of 18 and 45
* You have had a history for at least a year of COPD symptoms
* Your current asthma treatment is limited to short-acting beta-agonists(such as albuterol)
* You have a history of smoking one pack of cigarettes per day for 7 years
* You will not be away from home for more than 5 days during the study

Exclusion Criteria:

* You are unwilling to limit your alcohol use to less than 5 drinks per week
* You have been in a research study with an investigational drug or vaccine in the last 4 weeks
* You have donated blood in the last 4 weeks
* You have been hospitalized or had major surgery in the last 4 weeks
* You have been treated in the emergency room within the last 4 weeks or hospitalized within the last 3 months for your asthma
* You have a history of heart problems in the last 6 months
* You have a history of stomach problems
* You are unwilling to avoid grapefruit juice throughout the study
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years
* Established diagnosis of B-cell CLL by NCI Working Group criteria
* ≤1 previous line of chemotherapy
* Expected survival \>6 months
* Acceptable hematologic status, liver function, renal function, and pulmonary function
* Negative serum pregnancy test for both pre-menopausal women and for women who are \< 2 years after the onset of menopause
* Written informed consent

Exclusion Criteria:

* Prior treatment with interferon, rituximab or other monoclonal antibody
* Prior allogeneic bone marrow transplant (BMT) or autologous BMT or peripheral stem cell transplant (PBSCT) or patients who are considered to be candidates for allogeneic or autologous BMT or PSCT as assessed by their treating physician
* Fertile men or women of childbearing potential not using adequate contraception
* Severe Grade 3 or 4 non-hematological toxicity or prolonged (\> 2 weeks) Grade 3 or 4 cytopenia on prior fludarabine or nucleoside analogue regimen
* History of fludarabine-induced or clinically significant autoimmune cytopenia
* History of other malignancies within 2 years prior to study entry, except for adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low-grade early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent.
* Medical conditions requiring long term use (\> 1 month) of systemic corticosteroids
* Active bacterial, viral, or fungal infection requiring systemic therapy
* Severe cardiac disease
* Seizure disorders requiring anticonvulsant therapy
* Severe chronic obstructive pulmonary disease with hypoxemia
* Uncontrolled diabetes mellitus or hypertension
* Transformation to aggressive B-cell malignancy.
* Known infection with HIV, HCV, or hepatitis B
* Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study
* Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins
* Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
The Effects of Normobaric Hypoxia on Blood Glucose Levels.

The purpose of this research study is to observe whether there is a change in blood glucose levels in response to a 2 hour oral glucose tolerance tests (OGTT) during acute normobaric hypoxia (short term low oxygen levels at normal ambient air pressure).


Eligibility Criteria:
Inclusion Criteria (non-diabetics):

* Tricare Insurance Beneficiary (military insurance) receiving care at Nellis AFB
* 5 males with a BMI \< 25; 5 males with a BMI \> 25 at least 18 years of age (MOFH personnel and DoD beneficiaries).
* 5 females with a BMI \< 25; 5 females with a BMI \> 25 at least 18 years of age (MOFH personnel and DoD beneficiaries).

Exclusion Criteria (non-diabetics):

* History of abnormal fasting glucose.
* Pulmonary disease.
* Any medications that change glucose control to include systemic steroid and diabetic medications.
* History of claustrophobia.
* Pregnant or breast feeding.
* Non-English speaking.
* Physical inability to wear/use the ROBD2

Inclusion Criteria (diabetics):

-5 males and/or females, at least 18 years of age, that are type 2 diabetics (MOFH personnel and DoD beneficiaries).

Exclusion Criteria (diabetics):

* Pulmonary disease.
* History of claustrophobia.
* Pregnant or breast feeding.
* Non-English speaking.
* Physical inability to wear/use the ROBD2
Effects of Fish Oil in Alleviating Health Hazards Associated With Ozone Exposure

This study aims to evaluate whether dietary supplementation with fish oil can protect against the cardiopulmonary effects induced by ozone exposure.

The investigators will conduct a randomized controlled trial among 64 healthy young adults in Shanghai, China. The eligible participants will be randomly assigned in a 2\*2 factorial design to 1 of 4 groups: 1) fish oil and ozone exposure, 2) fish oil and shame exposure, 3) soy oil and ozone exposure, or 4) soy oil and shame exposure. The participants who take fish oil would receive 2.2 g/day (two 1.1-g capsules daily) in divided doses, and other participants will take the same amount of soy oil capsules. Two hour ozone exposure (200 ppb ozone) or shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation. Ozone is generated by a silent electric discharge method (HTU-500, AZCO Industries Ltd., Canada) and introduced into the chamber. The temperature and relative humidity in the chamber are maintained at 22±1℃ and 50%±5%, respectively. During the 2-hour exposure, each subject alternate 15 minutes of exercise on a treadmill and 15 minutes of rest. The exercise workload would be adjusted to achieve the targeted ventilation of 20±1 L/min/m2 body surface area. Health examinations will be conducted immediately prior to exposure, immediately after exposure, 2 hours after exposure and again the next morning.

Eligibility Criteria:
Inclusion Criteria:

* Living in Shanghai during study period;
* Ability to complete the training exercise to induce an inspired ventilation rate of 20±1 L/min/m2 body surface area;
* Body mass index \>18.5 and ≤30 (30 is the lower limit for class 2 obesity for Chinese);
* Taking the fish oil or placebo on time.

Exclusion Criteria:

* Being allergic to seafood;
* Smoking and alcohol abuse;
* Current drug and dietary supplements intake;
* Subjects with allergic disease, such as allergic rhinitis, allergic asthma, and atopy;
* Subjects with cardiovascular disease, such as congenital heart disease, pulmonary heart disease, and hypertension;
* Subjects with respiratory disease, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease;
* Subjects with chronic disease, such as diabetes, chronic hepatitis, and kidney disease;
* Subjects with a history of major surgery;
* Abnormal spirometry (FEV1 and FVC ≤ 75% of predicted and FEV1/FVC ≤ 0.65);
* Abnormal baseline 12-lead resting electrocardiogram;
* Abnormal blood index, such as cell counting, blood lipids, and glutamic-pyruvic transaminase (GPT).
Median Sternotomy in Penetrating Cardiac Trauma

The investigators aim to assess role of median sternotomy in penetrating cardiac trauma regarding morbidity and mortality of the patients.

Cardiac trauma is a leading cause of death in the USA and occurs mostly due to motor vehicle accidents. Cardiac trauma may be blunt or as a penetrating chest injuries, and both can lead to aortic injuries. The Right Ventricle followed by the Left Ventricle was the most common site of injury.

Timely diagnosis and early management are the key to improve mortality. Mortality related to cardiac trauma remains high despite improvement in diagnosis and management.

Assessment of suspected cardiac injuries in a trauma setting is a challenging and time-critical matter, with clinical and imaging findings having complementary roles in the formation of an accurate diagnosis. Cardiac computed tomography and cardiac ultrasound are the two most important diagnostic modalities.

Pericardial tamponade and haemothorax were common intra-operative findings. Patients having penetrating cardiac injury presenting with detectable signs of life on arrival to the hospital can be rescued by early surgical intervention.

Penetrating cardiac injuries are high-risk, high-mortality injuries considering the outcomes. Therefore, it is important to choose the appropriate incision. In general clinical settings, thoracotomy and median sternotomy are choices of incisions to explore the injury.

It is really important to transfer these patients to the nearest facility in time, make sure they get immediate diagnosis and proper resuscitation until they are ready to be taken into the operating room for exploration.

Eligibility Criteria:
Inclusion Criteria:

* A. Inclusion criteria:

Penetrating traumatic cardiac patients. B.age:patients aged from15 to 60 years old.

Exclusion Criteria:

* Patient who arrest immediately when arrived trauma unit.
* patients with polytrauma
* patients with chronic medical disease as asthma or ischemic herat disease
Nanofat in Post Burn Scars on the Face

Quasi-Experimental Study: Unfiltered Nanofat Injected into Postburn Facial Scars Number of Patients: 48 Outcome Assessed on POSAS And with Imaje J Scanning Preop And Postop Statistical Comparison of Scar Done

Objective: To compare the quality of post burn facial scars before and after injection of unfiltered nanofat.

Place and Duration of Study: Plastic Surgery Department, Mayo Hospital, Lahore, from January 2016 to December 2016.

Methodology: 48 patients with post burn facial scars were included, age range 4 to 32 years with Fitzpatrick skin types between 3 and 4. Patients with hypertrophic scars, contractures or keloids were excluded. Scars were assessed by a senior plastic surgeon and the patient on the POSAS. Fat was harvested from the abdomen and/or thighs with a 3 mm multi-port liposuction cannula (containing several sharp side holes of 1 mm) using Coleman's technique, emulsified, and transferred into 1 ml Leur lock syringes for injection into the subdermal or intradermal plane. Final follow up was scheduled at 6 months and scar was rated by the patient and the same surgeon on the POSAS. Pre and post op scar scores were compared and p-values calculated.

Eligibility Criteria:
Inclusion Criteria:

* Post burn scars on the face
* Fitzpatrick skin types between 3 and 4

Exclusion Criteria:

* Hypertrophic scars
* Contractures
* Keloids
Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

The purpose of this study is to describe the length of time and extent of blood pressure response to minoxidil and hydralazine among cancer patients with difficult-to-treat vascular endothelial growth factor (VEGF) inhibitor treatment induced hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Ongoing treatment for malignancy by at the University of Chicago with any agent with recognized, specific inhibition of VEGF, VEGF-receptors, or downstream signaling molecules with the specific intention of inhibiting signaling of this pathway. These agents include but are not limited to: bevacizumab (Avastin™), sorafenib (Nexavar™), sunitinib (Sutent™), axitinib (AG-013736), and AZD 2171.
* Treatment of hypertension with at least 2 or more anti-hypertensive medications with blood pressure remaining greater than 140/90 mmHg.
* Stable management of other toxicities from the cancer treatments
* Expected to continue current cancer treatments for at least 4 weeks
* 18 years and older
* Ability to understand and the willingness to sign a written informed consent document prior to any study specific procedures.

Exclusion Criteria:

* Concurrent use of hematopoietic supportive treatment with erythropoietin or congeners.
* Current uncontrolled toxicities due to the cancer treatments.
* Patients having known contraindications to hydralazine or minoxidil therapy.
* Any readings of systolic blood pressure \>200 mmHg or diastolic blood pressure \>120 mmHg in the four (4) weeks prior to screening.
* Use of either minoxidil or hydralazine in the six (6) months prior to screening.
The Effect of Using Medial Longitudinal Arch Supported Insoles on Jumping in Young Football Players

In this study, it was aimed to determine the effect of pressing styles and insoles on jumping performances.

In this clinical study, 30 healthy male football players between the ages of 16-20 will be carried out at Kasımpaşa Sports Club Academy. In the study, the effect of medial longitudinal arch height and the use of insoles on jumping using vertical jump, countermovement jump and drop jump tests will be investigated. Football players; Medial longitudinal arch heights will be measured by applying Foot Posture Index-6 and Navicular Position Test. As a result of these measurements; flat sole, normal sole and high sole will be divided into three groups. These three groups; Vertical jumping, countermovement jumping and drop jumping tests will be applied with the help of portable jumping apparatus and the results will be recorded. These tests will be re-applied to all three groups with a non-personalized, prefabricated insole that supports the medial arch. According to these tests, it will be investigated whether jumping performance depends on medial arch height. It will be evaluated whether there is a change in jumps after the insoles used. The obtained data will be analyzed statistically.

Eligibility Criteria:
Inclusion Criteria:

* Football players between the ages of 16-20 will be included in the study.
* Football players who were not injured at the time of the study were included in the study will be.
* Football players who allow and want to participate in the study will be included in the study.

Exclusion Criteria:

• Football players who had an injury at the time of the study were included in the study will not be.
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).


Eligibility Criteria:
Inclusion Criteria:

* Female and male participants:

  * Cohort 1: ≥ 12 years of age.
  * Cohort 2: 6 to \< 12 years of age.
  * Cohort 3: 2 to \< 6 years of age (after eDMC review of interim data from Cohort 2).
* Clinical diagnosis of FOP.
* Willingness to avoid pregnancy or fathering children based on the criteria below.
* Willing and able to undergo low-dose WBCT (excluding the head) imaging without requiring intubation.
* Further inclusion criteria apply.

Exclusion Criteria:

* Pregnant or breast-feeding.
* CAJIS score ≥ 24.
* FOP disease severity that in the investigator's opinion precludes participation.
* Any clinically significant medical condition other than FOP that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the participant, or interfere with interpretation of study data.
* Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
* HIV, HBV, or HCV infection. Note:
* Further exclusion criteria apply.